In a significant policy shift, Acting Attorney General Todd Blanche has signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This change, announced on Thursday, 23 April 2026, marks a major departure from the long-standing federal stance that cannabis has no medical use and a high potential for abuse.
What does the reclassification mean?
The reclassification means that medical marijuana is now officially recognized as having a moderate to low potential for dependence, rather than being lumped together with drugs like heroin and LSD. While this move does not legalize marijuana outright, it significantly alters its regulatory landscape. Key implications include tax breaks for state-licensed operators and eased restrictions on research, allowing scientists greater access to study the drug's medical benefits.
Impact on state programs
The order largely legitimizes medical marijuana programmes in the 40 US states that have adopted them. State-licensed producers and distributors will now be able to register with the Drug Enforcement Administration (DEA), a step that was previously impossible under the Schedule I classification. This registration is expected to streamline operations and reduce legal uncertainties for businesses operating in compliance with state laws.
Understanding Schedule III
Schedule III drugs are defined as substances with a moderate to low potential for physical and psychological dependence. Examples include anabolic steroids, testosterone, and ketamine. In contrast, Schedule I is reserved for drugs with no accepted medical use and a high potential for abuse, such as heroin, LSD, and ecstasy. Marijuana itself remains a Schedule I drug for non-medical use, but the reclassification of medical marijuana represents a nuanced shift in federal drug policy.
The decision has been welcomed by advocates of medical cannabis, who argue that the previous classification hindered research and imposed undue burdens on patients and businesses. Critics, however, caution that the move could lead to increased use and abuse. The full impact of this policy change remains to be seen as regulatory details are finalized.
